Recent News

• 11.06.2025 - Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
• 10.30.2025 - Travere Therapeutics Reports Third Quarter 2025 Financial Results
• 10.23.2025 - Travere Therapeutics to Report Third Quarter 2025 Financial Results
• 10.17.2025 - Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
• 09.26.2025 - CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

Recent Filings

• 11.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.04.2025 - 144 Report of proposed sale of securities
• 10.31.2025 - 144 Report of proposed sale of securities
• 10.31.2025 - 144 Report of proposed sale of securities
• 10.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.30.2025 - 8-K Current report
• 10.30.2025 - EX-99.1 EX-99.1